Verified peer comparison
Kymera Therapeutics vs United States Antimony Financial Comparison
Direct answer
Kymera Therapeutics and United States Antimony are compared on the same basis.
The comparison uses 2025 results reported in USD.
Common metrics include Revenue, Operating income, Net income, Operating cash flow.
Alpha Vantage
Get free Kymera Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Kymera Therapeutics Revenue
- 39,200,000 USD
- United States Antimony Revenue
- 39,257,708 USD
- Kymera Therapeutics Operating income
- -349,400,000 USD
- United States Antimony Operating income
- -8,877,337 USD